Clinical Scorecard: Safety of Biologic and Targeted Therapies in Relation to Tumor Risk in Immune-Mediated Inflammatory Arthritis

At a Glance

Key Highlights

• Patients with IMIA have increased cancer susceptibility due to persistent inflammation and other risk factors.
• Biologic therapies generally show reassuring safety profiles regarding overall malignancy.
• Non-melanoma skin cancer is a notable treatment-associated risk, especially with TNF inhibitors.
• JAK inhibitors require caution in specific risk-enriched populations.
• EULAR guidelines recommend individualized treatment decisions post-cancer remission.
• Individualized treatment decisions are crucial for patients with a history of cancer.

Guideline-Based Recommendations

Diagnosis

• Assess cancer risk factors including age, smoking, and prior malignancy.

Management

• Individualize therapy selection based on patient-specific factors and prior cancer history.

Monitoring & Follow-up

• Regularly evaluate for malignancy in patients receiving immunomodulatory therapies.
• Monitor specific cancer types associated with different therapies.

Risks

• Increased risk of lymphoma and lung cancer in patients with rheumatoid arthritis.

Patient & Prescribing Data

Biologic therapies may reduce inflammation-driven oncogenic pressure but also affect antitumor immune surveillance, necessitating careful consideration.

Clinical Best Practices

• Balance inflammatory control with oncologic vulnerability in treatment decisions.
• Consider cumulative inflammatory burden when evaluating malignancy risk.
• Ongoing risk assessment should be part of treatment management.

Related Resources & Content

• EULAR Guidance 2024